Loading...
•
Mar 31, 2024
Delcath Q1 2024 Earnings Report
Delcath reported first quarter 2024 results, highlighting revenue growth and strategic advancements.
Key Takeaways
Delcath Systems reported a significant increase in total revenue for Q1 2024, reaching $3.1 million compared to $0.6 million in the same period last year. The company is focused on expanding the availability of HEPZATO and is committed to reaching 20 treating centers by the end of 2024.
Recognized over $2.0 million in revenue from HEPZATO KIT sales and $1.1 million in CHEMOSAT sales.
Updated U.S. center activation guidance to a total of 20 active centers by the end of 2024.
Activated four treating centers during the first quarter, with an additional two in April.
Raised $7.0 million in a private placement transaction.
Revenue by Segment
Forward Guidance
Delcath is committed to expanding the availability of HEPZATO to patients in need and is confident that they will reach their goal of 20 treating centers by the end of 2024.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...